TABLE 2.
Comparison of FIB-4 and NFS for diagnostic performance of advanced hepatic fibrosis in various groups.
| Advanced fibrosis* n (%) |
Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | |
| FIB-4 to use low cut-off; 1.3 (2.0) | |||||
| Total subjects | 102 (2.6) | 69.6 | 77.5 | 4.9 | 99.3 |
| Non-fatty liver group | 39 (1.2) | 71.8 | 76.7 | 3.6 | 99.6 |
| Metabolically healthy group | 25 (0.8) | 64.0 | 78.2 | 2.2 | 99.6 |
| Fatty liver group | 63 (2.1) | 68.3 | 78.4 | 6.4 | 99.1 |
| Metabolically unhealthy group | 77 (2.6) | 71.4 | 76.7 | 7.7 | 99.0 |
| NFS to use low cut-off; –1.455 (0.12) | |||||
| Total subjects | 102 (2.6) | 61.4 | 81.1 | 5.2 | 99.2 |
| Non-fatty liver group | 39 (1.2) | 59.0 | 82.6 | 4.0 | 99.4 |
| Metabolically healthy group | 25 (0.8) | 44.0 | 89.0 | 3.0 | 99.5 |
| Fatty liver group | 63 (2.1) | 62.9 | 79.5 | 6.2 | 99.0 |
| Metabolically unhealthy group | 77 (2.6) | 67.1 | 72.1 | 6.1 | 98.8 |
*Prevalence of subjects with advanced hepatic fibrosis among total subjects (n = 6,215), and the non-fatty liver (n = 3,252), metabolically healthy (n = 3,291), fatty liver (n = 2,963), and metabolically unhealthy (n = 2,924) groups. FIB-4, fibrosis-4 index; MRE, magnetic resonance elastography; NFS, non-alcoholic fatty liver disease fibrosis score; NPV, negative predictive value; PPV, positive predictive value.